G$^9|UDIA>@|D7Q'%~3W-{,KG}X<U^/X'VXU
SYSTEM PROCESSING...
G$^9|UDIA>@|D7Q'%~3W-{,KG}X<U^/X'VXU
SYSTEM PROCESSING...
Posted: 2025-05-09 23:37:33 UTC
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
Status
Last Updated
2025-05-09 23:37:43 UTC
Verified By
Rollup News
The phase 2B clinical trial for SurVaxM, a therapeutic vaccine for glioblastoma, will proceed after meeting key benchmarks in an interim futility analysis. The vaccine targets survivin, a protein that helps glioblastoma cells evade death, and has shown strong safety and tolerability. Prior phase 2A results showed significantly improved one-year survival rates compared to historical norms.
SurVaxM phase 2B trial met interim review criteria to continue without changes.
SurVaxM attacks survivin, a protein essential for glioblastoma cell survival.
A prior phase 2A study showed 93.7% one-year survival, far above historical averages.
Glioblastoma is an aggressive brain cancer with few effective therapies.
Maintaining quality of life for patients facing glioblastoma.